Chronic Lymphocytic Leukemia (CLL)

CLL is the most common adult leukemia in Western countries, characterized by clonal proliferation of mature B lymphocytes in blood, bone marrow, and lymphoid tissues. Many patients are asymptomatic at diagnosis, and management ranges from observation to targeted therapy.

Symptoms & Signs

• Lymphadenopathy, splenomegaly
• Fatigue, night sweats, weight loss (B symptoms)
• Recurrent infections
• Cytopenias (anemia, thrombocytopenia)
• Autoimmune complications (AIHA, ITP) in some cases

Diagnosis

• Absolute lymphocytosis ≥ 5,000/µL for ≥3 months
• Flow cytometry: CD5+, CD19+, CD23+, dim surface Ig (CLL immunophenotype)
• Bone marrow biopsy usually not required but may help staging
• Imaging (CT/PET) for bulky disease or transformation suspicion

Staging & Prognosis

• Rai (0–IV) or Binet (A–C) staging systems
• Prognostic markers: IGHV mutation status, TP53 (17p deletion), NOTCH1, SF3B1, β2-microglobulin
• CLL-IPI integrates genetics + clinical factors

When to Treat

Indications include:

• Symptomatic or progressive lymphadenopathy/splenomegaly
• Worsening anemia (Hb < 10) or thrombocytopenia (< 100k)
• Constitutional symptoms (fatigue, night sweats, weight loss)
• Rapid lymphocyte doubling time (< 6 months)
• Autoimmune cytopenias refractory to steroids

Treatment Options

First-Line

• BTK inhibitors: ibrutinib, acalabrutinib, zanubrutinib
• BCL-2 inhibitor venetoclax + anti-CD20 antibody (obinutuzumab) for time-limited therapy
• Chemoimmunotherapy (FCR, BR) reserved for select young IGHV-mutated patients

Relapsed/Refractory

• Switch mechanism (BTK → venetoclax or vice versa)
• PI3K inhibitors (idelalisib, duvelisib) for specific cases
• Clinical trials for novel combinations

Supportive Care

• Vaccinations (influenza, COVID-19, pneumococcal, RSV; avoid live vaccines)
• Infection prophylaxis (antivirals, antifungals) during certain regimens
• Immunoglobulin replacement for severe hypogammaglobulinemia
• Monitor cardiovascular risk with BTK inhibitors
• Manage tumor lysis syndrome prophylaxis with venetoclax ramp-up

Special Situations

• Richter transformation (CLL → aggressive lymphoma) requires biopsy and aggressive therapy
• TP53/17p deletion: avoid chemo; use targeted regimens or consider allogeneic transplant

Living with CLL

• Track CBC trends, lymph node changes, infections, and side effects
• Maintain a healthy lifestyle: exercise, balanced diet, stress management
• Protect against infections (hand hygiene, masks in high-risk settings)
• Address fatigue/anxiety with counseling, support groups

Complications

• Opportunistic infections, shingles
• Autoimmune hemolytic anemia, immune thrombocytopenia
• Transformation to aggressive lymphoma (Richter)
• Second primary malignancies (skin cancer screening is critical)

Research & Future Directions

Investigations focus on next-gen BTK inhibitors (reversible, brain-penetrant), CAR-T cells, bispecific antibodies, and MRD-guided therapy.

Experimental & Emerging Treatments

• Non-covalent BTK inhibitors (pirtobrutinib) overcome resistance mutations.
• CAR-T & CAR-NK therapies targeting CD19/CD20 for heavily pretreated patients.
• Bispecific Antibodies (CD20xCD3) provide off-the-shelf T-cell redirecting options.
• MRD-Adaptive Therapy: Stopping treatment when minimal residual disease becomes undetectable to reduce toxicity.

Track CLL with Diagnoza.care

Stay Vigilant with Data – Log labs, lymph node measurements, imaging, treatment cycles, infections, vaccinations, and side effects; schedule hematology visits and infusion appointments; capture fatigue or mood changes; and let the AI companion highlight trends that trigger re-evaluation.

---

Medical Disclaimer: Informational only. Follow your hematologist/oncologist for risk stratification, treatment decisions, and surveillance plans. Sources: National Comprehensive Cancer Network, American Society of Hematology, Leukemia & Lymphoma Society